MIND MEDICINE MINDMED INC (MNMD) Stock News
NASDAQ:MNMD - Nasdaq - CA60255C8850 - Common Stock - Currency: USD
MNMD Latest News, Press Relases and Analysis
MindMed Announces New Employee Inducement Grants
Why Mind Medicine Gave Investors a Powerful Buzz in May
Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade
The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 237.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why Mind Medicine Stock Vaulted More Than 8% Higher Today
MindMed to Participate in June Investor Conferences
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.
Mind Medicine (MindMed) Inc. (MNMD): Analysts See 285% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) was one of the stocks that was covered in that article. Wall Street analysts believe MNMD has a 285% upside potential over the next 12 months. Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) is a clinical-stage biopharmaceutical company dedicated […]
Why Mind Medicine Stock Vaulted More Than 8% Higher Today
One state's House of Representatives just voted in favor of decriminalizing psilocybin. Shares of the psychedelic-focused biotech, which also goes by the name of MindMed, provided a nice high by rising more than 8% in price on a legislative development. Late on Monday, Connecticut's House of Representatives approved a bill to decriminalize psilocybin, the psychoactive compound found in so-called "magic" mushrooms.
MindMed Announces New Employee Inducement Grants
Was Jim Cramer Right About Mind Medicine (MNMD) Stock?
Back in 2024, on May 14, a caller brought up Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), a biotech company focused on psychedelic treatments for mental health. Cramer said he was supportive back then, particularly of companies tackling pain and addiction: “I like MindMed. I am a big believer in that, by the way. I’m in Vertex […]
Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?
The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 279.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference
MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025
MindMed Announces New Employee Inducement Grants
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)
MindMed Announces New Employee Inducement Grants
MindMed Appoints Matt Wiley as Chief Commercial Officer
Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish
The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier.
Mentions: CMPS
MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
MindMed to Present at Leerink’s Global Healthcare Conference 2025
MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.